Syndax Pharmaceuticals Inc. (SNDX) Gains Attention with Promising Drug Portfolio and Narrower-than-Expected Q2 Loss

Syndax Pharmaceuticals is capturing attention with its promising drug portfolio and financial performance. The company's commercial portfolio includes Revuforj and Niktimvo, and analysts predict a path to profitability in 2027. Syndax reported a narrower-than-expected loss of 83 cents per share on revenue of $37.96 million. Guggenheim Partners assumed coverage with a Buy rating and a price forecast of $34.